DOCSLIB.ORG

Immune Presentation and Recognition of Class I MHC Phosphopeptide Antigens

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Immune presentation and recognition of class I MHC phosphopeptide antigens by Daniel Henry Stones A thesis submitted to the University of Birmingham for the degree of DOCTOR OF PHILOSOPHY Supervisor: Professor Benjamin E. Willcox University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. Abstract Alterations to metabolic pathways, in particular post-translational modification, are a recognised hallmark of diseases such as autoimmunity, inflammation and cancer, and potentially provide a source of altered self antigens that can stimulate immune responses. Most notably, phosphorylated peptides have emerged as a group of tumour associated antigens which can be presented by MHC molecules and recognised by T-cells, and therefore represent promising candidates for future cancer immunotherapy strategies. However, how antigen phosphorylation impacts upon antigen presentation and recognition remains unclear. During this study I demonstrated that the phosphate moiety of phosphopeptides bearing the canonical P4 phosphorylation is more structurally diverse in its binding mode than previously thought. Strikingly, two epitopes exhibited a major conformational change upon addition of the phosphate moiety, effectively creating “conformational neoantigens”. This occurred through a similar mechanism for each epitope, whereby the presence of the phosphate moiety raised the position of the P4 Serine, allowing phosphate-mediated contacts with MHC residues and distorting the conformation of the central epitope region most critical for T- cell receptor recognition. Finally, I found that recognition of phosphopeptides can be both phosphate-dependent and epitope-specific at the level of the T-cell receptor. Therefore, this study shows that phosphorylation can have a profound and diverse effect on antigen binding, epitope identity and T-cell receptor recognition. In summary, my studies suggest that phosphopeptides are not only tumour associated but also highly antigenically distinct, establishing them as attractive candidates for cancer immunotherapy strategies. For Leanne and Ella Acknowledgements I would firstly like to thank my supervisor Ben Willcox for giving me the opportunity to undertake a PhD as part of his group and for all his support both in and out of the Lab. Also, thanks to Fiyaz Mohammed for mentoring in all things crystallography related and for all the collaborative efforts and late nights/early mornings spent shooting X-rays at crystals. A big thanks also to the past and present members of the Willcox lab; especially Carrie Willcox, Mahboob Salim and Sarah Nicholls, for all their help and advice in the lab and for mutual support during those much needed coffee breaks. Thanks to Mark Cobbold for discussions regarding HLA-B7 phosphoantigens and the cellular aspects of phosphoantigen presentation and recognition. I would like to thank Angela Zarling for providing the TCR gene constructs used for cloning into expression vectors and also Victor Engelhard and Kara Cummings for providing peptide affinity data on all of the phospho/nonphospho-peptides. Finally I would like to thank all my friends and family who have supported me over the course of this thesis, even when I was at my most stressed and irritable, this applies especially to Leanne, Ella and my parents, without your constant love and support this thesis would not have been possible. Contents 1 Introduction 1 1.1 Cancer and the immune system 1 1.1.1 Tumour biology 1 1.1.2 Evidence for tumour suppression by the immune system 3 1.2 Vertebrate Immunity 6 1.3 Antigen Presentation 13 1.3.1 Proteasomal degradation of cytosolic antigens 13 1.3.2 TAP transport 17 1.3.3 Antigen processing in the endoplasmic reticulum 18 1.3.4 Class I MHC structure 21 1.3.5 MHC-peptide binding and complex stability 24 1.3.6 Cross Presentation 25 1.4 Immunotherapy 26 1.4.1 Immunotherapy strategies 26 1.4.2 Challenges facing immunotherapy 28 1.5 Targeting post-translationally modified antigens as novel tumour antigens for immunotherapy 31 1.5.1 Types of post-translational modification 31 1.5.2 Phosphorylation 31 1.5.3 Presentation of phosphopeptide antigens 32 1.5.4 T-cell recognition of post-translational modified antigens 35 1.5.5 Phosphopeptides as novel tumour antigens for immunotherapy 36 1.6 Aims 37 2 Methods 39 2.1 Molecular Cloning Techniques 39 2.1.1 Plasmids 39 2.1.2 Bacterial cell culture 40 2.1.3 Preparation of chemically competent bacteria 40 2.1.4 Bacterial transformation with plasmid DNA 41 2.1.5 Insect S2 cell culture and transfection with plasmid DNA 41 2.1.6 Isolation of plasmid DNA 42 2.1.7 Polymerase chain reaction 42 2.1.8 Agarose gel electrophoresis 43 2.1.9 Gel purification of DNA 43 2.1.10 Restriction enzyme DNA digests and DNA ligation 44 2.1.11 DNA sequencing 44 2.2 General Protein Techniques 44 2.2.1 S2 insect cell protein expression 44 2.2.2 Ni-NTA column purification of His tagged proteins 45 2.2.3 E.coli protein expression 45 2.2.4 Inclusion body purification 46 2.2.5 SDS-PAGE 47 2.2.6 Quantification of protein 48 2.2.7 Protein refolding 49 2.2.8 Size exclusion chromatography 51 2.2.9 Anion and Cation exchange chromatography 51 2.2.10 Western blotting 51 2.2.11 3C cleavage of T-cell receptors 52 2.2.12 Biotinylation of protein complexes 52 2.3 Surface Plasmon Resonance 53 2.4 Overview of X-ray crystallography 53 2.4.1 Crystal generation 53 2.4.2 X-ray diffraction 58 2.4.3 Data processing, model building and refinement 58 2.4.4 Structural Verification, Analysis and Figure creation 59 3 Structural plasticity of phosphopeptide binding to HLA-A2 60 3.1 Background 60 3.2 HLA-A2-phosphopeptide complex production 61 3.3 Crystallisation of HLA-A2-phosphopeptide complexes 63 3.4 Data collection and processing 68 3.5 HLA-A2-phosphopeptide complex structure solution 68 3.6 HLA-A2-phosphopeptide structure refinement 71 3.7 Overall structure of HLA-A2-phosphopeptide complexes 74 3.8 Analysis of canonical phosphopeptide binding mode 77 3.9 Phosphate moiety effects on epitope binding affinity 86 3.10 Conclusions 88 4 Phosphate induced effects on HLA-A2 antigen identity 91 4.1 Background 91 4.2 HLA-A2-nonphosphopeptide complex production 92 4.3 Crystallisation 93 4.3.1 Crystallisation of HLA-A2-non-phosphopeptide complexes using commercial screens 93 4.3.2 Crystallisation of HLA-A2-non-phosphopeptide complexes with LILRB1 98 4.4 X-ray Data collection and Processing 102 4.5 HLA-A2-non-phosphopeptide complex structure solution 104 4.6 HLA-A2-non-phosphopeptide structure refinement 106 4.7 Overall Structure of HLA-A2-non-phosphopeptide complexes 108 4.8 Phosphate induced effects on epitope identity 112 4.9 Conclusions 130 5 Phosphopeptide antigen recognition by phosphopeptide specific T-cell receptors 134 5.1 Background 134 5.2 Production of soluble T-cell receptors 134 5.2.1 Expression vector cloning 134 5.2.2 Soluble T-cell receptor expression 135 5.3 IRS2 TCR binding studies 142 5.4 IRS2BK T-cell binding studies 144 5.5 CDC25B T-cell clone binding studies 148 5.6 Conclusions 162 6 Discussion 167 Appendices 177 References 199 List of Figures 1. Introduction Figure 1.1 Hallmarks of cancer 2 Figure 1.2 Cancer Immunoediting 4 Figure 1.3 Clonal Selection Theory 9 Figure 1.4 The proteasome 14 Figure 1.5 TAP transport of peptides 19 Figure 1.6 Pockets of the MHC-class I binding groove 23 2. Methods Figure 2.1 Two dimensional crystallisation phase diagram 55 Figure 2.2 Diagram of the hanging drop vapour diffusion method 57 3. Structural plasticity of phosphopeptide binding to HLA-A2 Figure 3.1 SDS-PAGE analysis of purified HLA-A2 and β2M inclusion bodies 62 Figure 3.2 Size exclusion chromatography purification of a typical HLA-A2- Phosphoeptide complex 64 Figure 3.3 SDS-PAGE analysis of refolded HLA-A2-phosphopeptide complex following purification by size exclusion chromatography 65 Figure 3.4 HLA-A2-phosphopeptide complex crystals used for X-ray diffraction 67 Figure 3.5 Typical example of HLA-A2-phosphopeptide X-ray diffraction pattern 69 Figure 3.6 Unbiased features of electron density maps 72 Figure 3.7 Ramachandran plot for HLA-A2-RLQpS complex 75 Figure 3.8 Overall structures of HLA-A2-phosphopeptide complexes 76 Figure 3.9 Individual phosphopeptide epitope structures 78 Figure 3.10 Orthogonal view of peptide binding groove 79 Figure 3.11 Plasticity of the canonical phosphopeptide binding mode 81 Figure 3.12 Phosphate mediated contacts 82 Figure 3.13 The accommodation of anchor residues in HLA-A2 phosphopeptides 84 4. Phosphate induced effects on HLA-A2 antigen identity Figure 4.1 Size exclusion chromatography purification of a typical HLA-A2- nonphosphopeptide complex 94 Figure 4.2 SDS-PAGE analysis of purified HLA-A2-nonphosphopeptide complex used for crystallisation 95 Figure 4.3 Crystals of HLA-A2-nonphosphopeptide complexes 97 Figure 4.4 Comparison of HLA-A2 structure with and without LILRB1 99 Figure 4.5 X-ray diffraction patterns of HLA-A2-RQISnp and LILRB1-HLA-A2-RTFSnp complexes 103 Figure 4.6 Overall structure of HLA-A2-nonphosphopeptide and LILRB1-HLA-A2-
Recommended publications
  • Activation of Naıve CD4 T Cells by Anti-CD3 Reveals an Important Role for Fyn in Lck-Mediated Signaling

    Activation of Naıve CD4 T Cells by Anti-CD3 Reveals an Important Role for Fyn in Lck-Mediated Signaling

    Activation of naı¨ve CD4 T cells by anti-CD3 reveals an important role for Fyn in Lck-mediated signaling Katsuji Sugie*, Myung-Shin Jeon†, and Howard M. Grey*‡ Divisions of *Vaccine Discovery and †Cell Biology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121 Contributed by Howard M. Grey, August 23, 2004 Although there was no impairment in IL-2 secretion and prolifer- Fyn-deficient T cells by antigen-pulsed APCs led to a robust ation of Fyn-deficient naı¨veCD4 cells after stimulation with anti- proliferative and IL-2 response, whereas anti-CD3-mediated gen and antigen-presenting cells, stimulation of these cells with stimulation revealed a profound signaling defect in Fyn-deficient anti-CD3 and anti-CD28 revealed profound defects. Crosslinking of T cells. This defect could be corrected by the cocrosslinking of purified wild-type naı¨veCD4 cells with anti-CD3 activated Lck and CD3 with CD4. Furthermore, the signaling defect of Fyn- initiated the signaling cascade downstream of Lck, including phos- deficient T cells stimulated with anti-CD3 was restricted to naı¨ve phorylation of ZAP-70, LAT, and PLC-␥1; calcium flux; and dephos- T cells and was not observed when Fyn-deficient effector T cells phorylation and nuclear translocation of the nuclear factor of were analyzed. Biochemical experiments on anti-CD3 stimulated activated T cells (NFAT)p. All of these signaling events were cells strongly suggest that the presence of Fyn was necessary for diminished severely in Fyn-deficient naı¨ve cells activated by CD3 an effective recruitment and͞or activation of Lck in the region crosslinking.
  • Generation and Characterization of New Monoclonal Antibodies Targeting the PHF1 and AT8 Epitopes on Human Tau Kevin H

    Generation and Characterization of New Monoclonal Antibodies Targeting the PHF1 and AT8 Epitopes on Human Tau Kevin H

    Strang et al. Acta Neuropathologica Communications (2017) 5:58 DOI 10.1186/s40478-017-0458-0 RESEARCH Open Access Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau Kevin H. Strang1,2, Marshall S. Goodwin1,2, Cara Riffe1,2, Brenda D. Moore1,2, Paramita Chakrabarty1,2,3, Yona Levites1,2,3, Todd E. Golde1,2,3 and Benoit I. Giasson1,2,3,4* Abstract Tauopathies are a group of neurodegenerative disorders, including Alzheimer’s disease, defined by the presence of brain pathological inclusions comprised of abnormally aggregated and highly phosphorylated tau protein. The abundance of brain tau aggregates correlates with disease severity and select phospho-tau epitopes increase at early stages of disease. We generated and characterized a series of novel monoclonal antibodies directed to tau phosphorylated at several of these phospho-epitopes, including Ser396/Ser404, Ser404 and Thr205. We also generated phosphorylation independent antibodies against amino acid residues 193–211. We show that most of these antibodies are highly specific for tau and strongly recognize pathological inclusions in human brains and in a transgenic mouse model of tauopathy. They also reveal epitope-specific differences in the biochemical properties of Alzheimer’s disease sarkosyl-insoluble tau. These new reagents will be useful for investigating the progression of tau pathology and further as tools to target the cellular transmission of tau pathology. Keywords: Alzheimer’s disease, Antibodies, Phosphorylation, Tau, Transgenic mice Introduction The abundance of tau inclusions in the brain correlates well Tau refers to the microtubule-associated protein [10, 47] with disease severity [2].
  • Mass Spectrometry–Based Identification of MHC-Bound

    Mass Spectrometry–Based Identification of MHC-Bound

    PROTOCOL https://doi.org/10.1038/s41596-019-0133-y Mass spectrometry–based identification of MHC-bound peptides for immunopeptidomics Anthony W. Purcell 1*, Sri H. Ramarathinam 1 and Nicola Ternette2* Peptide antigens bound to molecules encoded by the major histocompatibility complex (MHC) and presented on the cell surface form the targets of T lymphocytes. This critical arm of the adaptive immune system facilitates the eradication of pathogen-infected and cancerous cells, as well as the production of antibodies. Methods to identify these peptide antigens are critical to the development of new vaccines, for which the goal is the generation of effective adaptive immune responses and long-lasting immune memory. Here, we describe a robust protocol for the identification of MHC-bound peptides from cell lines and tissues, using nano-ultra-performance liquid chromatography coupled to high-resolution mass spectrometry (nUPLC–MS/MS) and recent improvements in methods for isolation and characterization of these peptides. The protocol starts with the immunoaffinity capture of naturally processed MHC-peptide complexes. The peptides dissociate from the class I human leukocyte antigens (HLAs) upon acid denaturation. This peptide cargo is then extracted and separated into fractions by HPLC, and the peptides in these fractions are identified using nUPLC–MS/MS. With this protocol, several thousand peptides can be identified from a wide variety of cell types, including cancerous and infected cells and those from tissues, with a turnaround time of 2–3d. 1234567890():,; 1234567890():,; Introduction The recognition of foreign antigens by T lymphocytes is the cornerstone of adaptive immunity. Specifically, intracellular antigens are degraded in the cytosol and antigenic precursor peptides are transported to the endoplasmic reticulum, where they are further trimmed to short peptides (8–11 amino acids (aa)) that can assemble with class I HLAs.
  • Rescue of Autophagy and Lysosome Defects in Salivary Glands of MRL/ Lpr Mice by a Therapeutic Phosphopeptide

    Rescue of Autophagy and Lysosome Defects in Salivary Glands of MRL/ Lpr Mice by a Therapeutic Phosphopeptide

    Journal of Autoimmunity xxx (2018) 1e14 Contents lists available at ScienceDirect Journal of Autoimmunity journal homepage: www.elsevier.com/locate/jautimm Rescue of autophagy and lysosome defects in salivary glands of MRL/ lpr mice by a therapeutic phosphopeptide * Baihui Li a, b, 1, Fengjuan Wang a, b, 1, Nicolas Schall a, b, Sylviane Muller a, b, c, a CNRS, Biotechnology and Cell Signaling, University of Strasbourg, France b Laboratory of Excellence Medalis, France c University of Strasbourg Institute for Advanced Study (USIAS), Strasbourg, France article info abstract Article history: Sjogren's€ syndrome is a multifactorial systemic autoimmune disorder characterized by lymphocytic in- Received 20 December 2017 filtrates in exocrine organs. Patients present with sicca symptoms, such as extensive dry eyes and dry Received in revised form mouth, and parotid enlargement. Other serious complications include profound fatigue, chronic pain, 13 February 2018 major organ involvement, neuropathies and lymphomas. Current treatments only focus on relieving Accepted 17 February 2018 symptoms and do not target the origin of the disease, which is largely unknown. The question we Available online xxx addressed here was whether some defects exist in autophagy processes in Sjogren's€ syndrome and if they can be corrected or minimized using an appropriate mechanism-driven treatment targeting this Keywords: € Autophagy central survival pathway. Using a recognized murine model of secondary Sjogren's syndrome, we fi Lysosomal dysfunction identi ed molecular alterations of autophagy occurring in the salivary glands of MRL/lpr mice, and MRL/lpr mice discovered that opposite (up- or down-regulated) autophagy events can arise in distinct organs of the P140 peptide same mouse strain, here in lymphoid organs and salivary glands.
  • Identification of Shared Phosphopeptide Tumor Targets in Colorectal Cancer for Novel Off-The-Shelf Vaccine Development Paisley T

    Identification of Shared Phosphopeptide Tumor Targets in Colorectal Cancer for Novel Off-The-Shelf Vaccine Development Paisley T

    Identification of Shared Phosphopeptide Tumor Targets in Colorectal Cancer for Novel Off-the-shelf Vaccine Development Paisley T. Myers1, Erin D. Jeffery1, Benjamin Morin1, Christine Brittsan1, Bishnu Joshi1, Antoine Tanne1, Karen Smith1, Albert Hurwitz1, Kara L. Cummings2, Amanda M. Lulu2, Daniel Levey1, Linh Mach1, Mark Findeis1, Victor H. Engelhard2, Jeffrey Shabanowitz3, Donald F. Hunt3, Arthur A. Hurwitz4, Robert Stein1, Alex Duncan1, Dennis Underwood1 1. Agenus Inc., Lexington, MA 02421, USA, 2. Department of Microbiology, Immunology, and Cancer Biology, Carter Immunology Center, University of Virginia School of Medicine, Charlottesville, VA 22901, USA, 3. Department of Chemistry, University of Virginia, Charlottesville, Virginia 22904, USA, 4. AgenTus Therapeutics, Inc., Lexington, MA, 02421, USA INTRODUCTION PHOSPHOLIGANDOME ANALYSIS OF CRC PATIENT TISSUES Immunoaffinity Lysis Purification Phosphopeptide Length Phosphorylated Site Phosphorylated Residue The high mortality rate of colorectal cancer (CRC) reflects STAGE Tip Sample Resected CRC Tissue Cleanup pTyr (27 Patients) 300 400 limitations of current treatment modalities aimed at targeting the 1% 350 250 pThr disease. Immunotherapy is a promising alternative to traditional 9% Normal 300 200 chemotherapy, yet its benefit has been limited to patients with high 250 mutational burden. 150 200 # PTTs 0.5 g tissue or 500 million # PTTs Tumor 150 cell equivalents 100 Phosphopeptide Tumor Targets (PTTs) represent a novel class 100 pSer 90% 50 of neoantigens which arise from dysregulated cellular signaling, 50 0 0 are presented by HLA class I molecules, and are recognized as 7 8 9 10 11 12 13 14 15 16 1 2 3 4 5 6 7 8 9 10 11 IMAC Phosphopeptide HPLC-ESI-MS/MS Analysis and Number of Residues Position antigenic by circulating cytotoxic T cells.
  • Critical Review of Existing MHC I Immunopeptidome Isolation Methods

    Critical Review of Existing MHC I Immunopeptidome Isolation Methods

    molecules Review Critical Review of Existing MHC I Immunopeptidome Isolation Methods Alexandr Kuznetsov 1, Alice Voronina 1 , Vadim Govorun 1,2 and Georgij Arapidi 2,3,4,* 1 Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia; [email protected] (A.K.); [email protected] (A.V.); [email protected] (V.G.) 2 Department of Molecular and Translational Medicine, Moscow Institute of Physics and Technology (State University), 141701 Dolgoprudny, Russia 3 Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia 4 Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia * Correspondence: [email protected]; Tel.: +7-926-471-1420 Academic Editor: Luca D. D’Andrea Received: 5 October 2020; Accepted: 17 November 2020; Published: 19 November 2020 Abstract: Major histocompatibility complex class I (MHC I) plays a crucial role in the development of adaptive immune response in vertebrates. MHC molecules are cell surface protein complexes loaded with short peptides and recognized by the T-cell receptors (TCR). Peptides associated with MHC are named immunopeptidome. The MHC I immunopeptidome is produced by the proteasome degradation of intracellular proteins. The knowledge of the immunopeptidome repertoire facilitates the creation of personalized antitumor or antiviral vaccines. A huge number of publications on the immunopeptidome diversity of different human and mouse biological samples—plasma, peripheral blood mononuclear cells (PBMCs), and solid tissues, including tumors—appeared in the scientific journals in the last decade.
  • Manipulating Autophagic Processes in Autoimmune Diseases: a Special Focus on Modulating Chaperone-Mediated Autophagy, an Emerging Therapeutic Target

    Manipulating Autophagic Processes in Autoimmune Diseases: a Special Focus on Modulating Chaperone-Mediated Autophagy, an Emerging Therapeutic Target

    REVIEW published: 19 May 2015 doi: 10.3389/fimmu.2015.00252 Manipulating autophagic processes in autoimmune diseases: a special focus on modulating chaperone-mediated autophagy, an emerging therapeutic target Fengjuan Wang 1 and Sylviane Muller 1,2* 1 Immunopathology and Therapeutic Chemistry/Laboratory of Excellence MEDALIS, CNRS, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France, 2 University of Strasbourg Institute for Advanced Study, Strasbourg, France Autophagy, a constitutive intracellular degradation pathway, displays essential role in the homeostasis of immune cells, antigen processing and presentation, and many other immune processes. Perturbation of autophagy has been shown to be related to several autoimmune syndromes, including systemic lupus erythematosus. Therefore, modulating Edited by: autophagy processes appears most promising for therapy of such autoimmune diseases. Stephanie Hugues, Université de Genève, Suisse Autophagy can be said non-selective or selective; it is classified into three main forms, Reviewed by: namely macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA), Xinjian Chen, the former process being by far the most intensively investigated. The role of CMA remains University of Utah, USA Willem Van Eden, largely underappreciated in autoimmune diseases, even though CMA has been claimed Utrecht University, Netherlands to play pivotal functions into major histocompatibility complex class II-mediated antigen *Correspondence: processing and presentation. Therefore, hereby, we
  • Inhibition of Natural Killer Cell Activation Signals by Killer Cell Immunoglobulin-Like Receptors

    Inhibition of Natural Killer Cell Activation Signals by Killer Cell Immunoglobulin-Like Receptors

    Eric O. Long Inhibition of natural killer cell Domingo F. Barber Deborah N. Burshtyn activation signals by killer cell Mathias Faure immunoglobulin-like receptors Mary Peterson Sumati Rajagopalan (CD158) Vale´ry Renard Mina Sandusky Christopher C. Stebbins Nicolai Wagtmann Carsten Watzl Authors’ addresses Summary: The killer cell immunoglobulin-like receptor (KIR) family in- Eric O. Long1, Domingo F. Barber1, cludes receptors that bind to HLA class I molecules on target cells and Deborah N. Burshtyn2, Mathias Faure1, Mary Peterson1, inhibit natural killer (NK)-cell cytotoxicity, and receptors such as Sumati Rajagopalan1, Vale´ry Renard3, Mina Sandusky1, KIR3DL7 with no known ligand and function. Inhibitory KIR recruit the Christopher C. Stebbins1, Nicolai Wagtmann4, tyrosine phosphatase SHP-1 to block signals transduced by any one of Carsten Watzl1, a number of activation receptors. Inhibition of overall protein tyrosine 1Laboratory of Immunogenetics, National phosphorylation by SHP-1 during binding of KIR to MHC class I on Institute of Allergy and Infectious Diseases, target cells is selective, suggesting that a limited number of substrates are National Institutes of Health, Rockville, dephosphorylated by SHP-1. We have chosen to study KIR inhibition as Maryland, USA. it occurs during binding of KIR to MHC class I on target cells, despite 2Department of Medical Microbiology and the technical limitations inherent to studies of processes regulated by Immunology, Heritage Medical Research cell contact. KIR binding to MHC class I on target cells inhibits tyrosine Centre, University of Alberta, Edmonton, phosphorylation of the activation receptor 2B4 (CD244) and disrupts Alberta, Canada. adhesion of NK cells to target cells. Inhibition of proximal events in NK 3M&E Biotech, Copenhagen, Denmark.
  • MHC-Restricted Phosphopeptide Antigens

    MHC-Restricted Phosphopeptide Antigens

    Open access Original research MHC- restricted phosphopeptide J Immunother Cancer: first published as 10.1136/jitc-2019-000262 on 7 May 2020. Downloaded from antigens: preclinical validation and first- in- humans clinical trial in participants with high- risk melanoma 1 1 1 Victor H Engelhard , Rebecca C Obeng , Kara L Cummings, Gina R Petroni,2 Angela L Ambakhutwala,1 Kimberly A Chianese- Bullock,3 Kelly T Smith,3 Amanda Lulu,1 Nikole Varhegyi,2 Mark E Smolkin,2 Paisley Myers,4 Keira E Mahoney,4 Jeffrey Shabanowitz,4 Nico Buettner,5 Emily H Hall,6 Kathleen Haden,3 Mark Cobbold,5 Donald F Hunt,4 Geoffrey Weiss,7 Elizabeth Gaughan,7 Craig L Slingluff, Jr3 To cite: Engelhard VH, ABSTRACT pBCAR3126-134 peptide in 2/12 patients (17%, 90% CI 3% Obeng RC, Cummings KL, et al. Background Phosphorylated peptides presented by to 44%). MHC- restricted phosphopeptide MHC molecules represent a new class of neoantigens Conclusion This study supports the safety and antigens: preclinical validation expressed on cancer cells and recognized by CD8 T- immunogenicity of vaccines containing the cancer- and first- in- humans clinical associated phosphopeptides pBCAR3 and pIRS2 trial in participants with high- cells. These peptides are promising targets for cancer 126-134 1097- , and the data support continued development of risk melanoma. Journal for immunotherapy. Previous work identified an HLA- A*0201- 1105 ImmunoTherapy of Cancer restricted phosphopeptide from insulin receptor substrate immune therapy targeting phosphopeptides. Future studies 2020;8:e000262. doi:10.1136/ 2 (pIRS2) as one such target. The purpose of this study will define ways to further enhance the magnitude and jitc-2019-000262 was to characterize a second phosphopeptide, from breast durability of phosphopeptide- specific immune responses.
  • Synthetic Phosphopeptide Immunogens Yield Activation-Specific Antibodies to the C-Erbb-2 Receptor (Trosine Kinases/Oncogencs/Phophorylation/Breast Neopsims) RICHARD J

    Synthetic Phosphopeptide Immunogens Yield Activation-Specific Antibodies to the C-Erbb-2 Receptor (Trosine Kinases/Oncogencs/Phophorylation/Breast Neopsims) RICHARD J

    Proc. Natl. Acad. Sci. USA Vol. 89, pp. 10435-10439, November 1992 Medical Sciences Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor (trosine kinases/oncogencs/phophorylation/breast neopsims) RICHARD J. EPSTEIN*t, BRIAN J. DRUKER*t, THOMAS M. ROBERTS*1, AND CHARLES D. STILES*§ *Division of Cell and Molecular Biology, Dana-Farber Cancer Institute, and Departments of tMedicine, VPathology, and §Microbiology and Molecular Genetics, Harvard Medical School, 44 Binney Street, Boston, MA 02115 Communicated by Robert A. Weinberg, July 29, 1992 ABSTRACT We inoculated rabbits with synthetic phos- 10% (vol/vol) bovine calf serum, glutamine (60 mg/liter), phopeptides, duplicating a major autophosphorylation site of penicillin (10 units/ml), streptomycin (0.1 ,ug/ml), and 0.3 the c-rbB-2 protooncogene product. The rabbits produced AuM methotrexate. All other cell lines were obtained from the antisera that, after reverse immunaffinity purfcation, selec- American Type Culture Collection. Cell manipulation, im- tively recognize the erbB-2 protein in its enzymaticafly active munoblot protocols, polyacrylamide gel electrophoresis, and configuration. These anti-phosphopeptide antisera identify a reagents were as described (11). Cells were lysed in lysis subset of erbB-2-positive human cell lines wherein the protein buffer (LB) consisting of10 mM Na2HPO4, 10 mM NaH2PO4, is constitutively active as a tyrosine kinase. Synthetic phos- 150 mM NaCI, 1% Nonidet P.40, 10%6 (vol/vol) glycerol, 50 phopeptides incorporating informative protein phosphoryla- mM sodium fluoride, 10 mM sodium pyrophosphate, prote- tion sites may prove useful for generating antibodies that ase inhibitors [40 indicate the activation state of additional tyrosine kinases and ,uM leupeptin, aprotinin (10 ,ug/ml), and 1 perhaps other proteins phosphorylated on serine and threonine mM phenylmethylsulfonyl fluoride], and tyrosine phospha- residues.
  • Peptides Class I Molecules Presenting Phosphorylated Reduced KIR2DL1 Recognition Of

    Peptides Class I Molecules Presenting Phosphorylated Reduced KIR2DL1 Recognition Of

    Reduced KIR2DL1 Recognition of MHC Class I Molecules Presenting Phosphorylated Peptides This information is current as Gili Betser-Cohen, Gil Katz, Tsufit Gonen-Gross, Noam of October 2, 2021. Stern, Tal I. Arnon, Hagit Achdout, Roi Gazit and Ofer Mandelboim J Immunol 2006; 176:6762-6769; ; doi: 10.4049/jimmunol.176.11.6762 http://www.jimmunol.org/content/176/11/6762 Downloaded from References This article cites 46 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/176/11/6762.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 2, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Reduced KIR2DL1 Recognition of MHC Class I Molecules Presenting Phosphorylated Peptides1 Gili Betser-Cohen, Gil Katz, Tsufit Gonen-Gross, Noam Stern, Tal I. Arnon, Hagit Achdout, Roi Gazit, and Ofer Mandelboim2 As initially described by K.
  • Quantitative Phosphoproteomic Analysis of T Cell Receptor Signaling in Diabetes Prone and Resistant Mice

    Quantitative Phosphoproteomic Analysis of T Cell Receptor Signaling in Diabetes Prone and Resistant Mice

    Quantitative Phosphoproteomic Analysis of T Cell Receptor Signaling in Diabetes Prone and Resistant Mice Leo K. Iwai,† Christophe Benoist,*,† Diane Mathis,*,† and Forest M White‡ Department of Pathology, Harvard Medical School and Section on Immunology and Immunogenetics, Joslin Diabetes Center, Boston, Massachusetts, and Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts Received January 15, 2010 Type 1 diabetes, in human patients and NOD mice, results from an immune attack on insulin-producing beta-cells of the pancreas by autoreactive T lymphocytes. In NOD mice, genetically controlled perturbations in the signaling pathways downstream of the antigen-specific T cell receptor (TCR) may be instrumental in the altered responses of T cells, manifest as inefficient induction of apoptosis after recognition of self-antigens in the thymus or as perturbed reactivity of mature T cells in peripheral organs. To map this signaling difference(s), we have used mass spectrometry-based quantitative phosphoproteomics to compare the activation of primary CD4+ T cells of diabetes-prone NOD and -resistant B6.H2g7 mice. Immunoprecipitation and IMAC purification of tyrosine-phosphorylated peptides, combined with a stable-isotope iTRAQ labeling, enabled us to identify and quantify over 77 phosphorylation events in 54 different proteins downstream of TCR stimulation of primary CD4+ T cells. This analysis showed a generally higher level of phosphotyrosine in activated NOD cells, as well as several phosphorylation sites that appeared to be differentially regulated in these two strains (involving TXK, CD5, PAG1, and ZAP-70). These data highlight the differences in signaling between CD4+ T cell compartments of NOD and B6g7 mice and may underlie the dysregulation of T cells in NOD mice.